Clinical Trials Directory

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma

This Phase II, multicenter, randomized, double-blind, placebo-controlled trial was designed to estimate the efficacy and characterize the safety of bevacizumab when combined with carboplatin + paclitaxel chemotherapy compared with carboplatin + paclitaxel chemotherapy alone in patients with previously untreated metastatic melanoma.

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • drug : bevacizumab
  • drug : placebo
  • drug : paclitaxel
  • drug : carboplatin

Phase: Phase 2


Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

- Signed Informed Consent Form - Age ? 18 years - Metastatic melanoma (Stage IV) - Histologically confirmed malignant melanoma with measurable or non-measurable disease - Ability and willingness to comply with study and follow-up procedures

External Links

Explore related trials

Contact information

Primary Contact:

Sunil Arani Reddy 6507361234

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: